CCR2 and neoplasm: As shown in Fig. 5c-d, the CCR2 antagonist blunted the reduction in tumor growth (mean volume in mm3 at day 10: vehicle = 110.4; RvD1 = 68.23, CCR2 antagonist = 88.51; CCR2 antagonist+RvD1 = 155.8) as well as the improvement in survival observed in RvD1-treated mice.